Mild Cognitive Impairment - Pipeline Review, H1 2015

Published: Apr, 2015 | Pages: 91 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Mild Cognitive Impairment - Pipeline Review, H1 2015

Summary 

Global Markets Direct's, 'Mild Cognitive Impairment - Pipeline Review, H1 2015', provides an overview of the Mild Cognitive Impairment's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Mild Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mild Cognitive Impairment and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Mild Cognitive Impairment and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Mild Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Mild Cognitive Impairment pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason To Buy 

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Mild Cognitive Impairment
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Mild Cognitive Impairment pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Mild Cognitive Impairment Overview 9
Therapeutics Development 10
Pipeline Products for Mild Cognitive Impairment - Overview 10
Pipeline Products for Mild Cognitive Impairment - Comparative Analysis 11
Mild Cognitive Impairment - Therapeutics under Development by Companies 12
Mild Cognitive Impairment - Therapeutics under Investigation by Universities/Institutes 13
Mild Cognitive Impairment - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Mild Cognitive Impairment - Products under Development by Companies 16
Mild Cognitive Impairment - Products under Investigation by Universities/Institutes 18
Mild Cognitive Impairment - Companies Involved in Therapeutics Development 19
Actinogen Limited 19
Avraham Pharmaceuticals Ltd. 20
Boehringer Ingelheim GmbH 21
D-Pharm Ltd. 22
Eisai Co., Ltd. 23
Eli Lilly and Company 24
FORUM Pharmaceuticals Inc. 25
Octapharma AG 26
Sage Therapeutics 27
Sanofi 28
Suven Life Sciences Ltd. 29
Mild Cognitive Impairment - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
BAN-2401 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
BCA-909 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
CSP-1103 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
DAOI-B - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
DP-NDD - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
FRM-0962 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
immune globulin (human) - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ladostigil tartrate - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
levetiracetam - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
LY-3002813 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Peptide T - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
SAGE-547 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
SAR-228810 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for CNS Disorders - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
SUVN-501 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
SUVN-502 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
SUVN-507 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
SUVN-512 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
SUVN-976 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
SUVND-4010 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
tropisetron hydrochloride - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
UE-2343 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Mild Cognitive Impairment - Recent Pipeline Updates 69
Mild Cognitive Impairment - Dormant Projects 80
Mild Cognitive Impairment - Discontinued Products 82
Mild Cognitive Impairment - Product Development Milestones 83
Featured News & Press Releases 83
Jul 08, 2014: Avraham Pharmaceuticals Announces Successful Interim Results in Phase 2b Study of Ladostigil for the Treatment of MCI 83
Jul 26, 2013: CERESPIR INCORPORATED IS PLEASED WITH POSITIVE INTERIM PHASE 2 RESULTS FOR CHF 5074 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT, PRESENTED BY CHIESI AT THE AAIC 2013 MEETING IN BOSTON 83
May 17, 2012: Avraham Initiates Phase II Ladostigil Study For Treatment Of Mild Cognitive Impairment 84
Jul 27, 2009: Suven Presented Positive Phase-I Clinical Data Of SUVN-502 For Alzheimer's Disease At ICAD 2009, Vienna, Austria. 85
Apr 09, 2009: Suven Completes Phase I Clinical Trials Multiple Ascending Dose Of SUVN-502 In Switzerland 86
Oct 13, 2008: Suven Announces That SUVN-502 Data Is Being Presented At 16th BioPartnering In London 86
Sep 29, 2008: Suven Completes Phase-I Clinical Trials Single Ascending Dose Of Suvn-502 In Switzerland 87
Sep 25, 2008: Suven Life Sciences Ltd. Announces DCGI Nod To Conduct Phase-I Clinical Trials Of Suvn-502 For Alzheimer'S Disease 87
Aug 04, 2008: Suven Life Sciences Presents Positive Preclinical Data For Suvn-502 At Alzheimer'S Conference, Chicago And Drug Discovery Conference, Boston 88
Jul 07, 2008: Suven Life Sciences' Clinical Candidate Suvn-502 Being Presented At International Conference On Alzheimer'S Disease, ICAD-2008 At Chicago, USA 89
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 90
Disclaimer 91

List of Tables

Number of Products under Development for Mild Cognitive Impairment, H1 2015 10
Number of Products under Development for Mild Cognitive Impairment - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Development by Companies, H1 2015 (Contd..1) 17
Products under Investigation by Universities/Institutes, H1 2015 18
Mild Cognitive Impairment - Pipeline by Actinogen Limited, H1 2015 19
Mild Cognitive Impairment - Pipeline by Avraham Pharmaceuticals Ltd., H1 2015 20
Mild Cognitive Impairment - Pipeline by Boehringer Ingelheim GmbH, H1 2015 21
Mild Cognitive Impairment - Pipeline by D-Pharm Ltd., H1 2015 22
Mild Cognitive Impairment - Pipeline by Eisai Co., Ltd., H1 2015 23
Mild Cognitive Impairment - Pipeline by Eli Lilly and Company, H1 2015 24
Mild Cognitive Impairment - Pipeline by FORUM Pharmaceuticals Inc., H1 2015 25
Mild Cognitive Impairment - Pipeline by Octapharma AG, H1 2015 26
Mild Cognitive Impairment - Pipeline by Sage Therapeutics, H1 2015 27
Mild Cognitive Impairment - Pipeline by Sanofi, H1 2015 28
Mild Cognitive Impairment - Pipeline by Suven Life Sciences Ltd., H1 2015 29
Assessment by Monotherapy Products, H1 2015 30
Number of Products by Stage and Target, H1 2015 32
Number of Products by Stage and Mechanism of Action, H1 2015 34
Number of Products by Stage and Route of Administration, H1 2015 36
Number of Products by Stage and Molecule Type, H1 2015 38
Mild Cognitive Impairment Therapeutics - Recent Pipeline Updates, H1 2015 69
Mild Cognitive Impairment - Dormant Projects, H1 2015 80
Mild Cognitive Impairment - Dormant Projects (Contd..1), H1 2015 81
Mild Cognitive Impairment - Discontinued Products, H1 2015 82